Comparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes

被引：0
|
作者：
Moon, Jungyeon [1 ]
Ozaki, Aya F. [2 ]
Chong, Alice [3 ]
Sud, Maneesh [4 ]
Fang, Jiming [3 ]
Austin, Peter C. [3 ]
Ko, Dennis T. [3 ,4 ,5 ]
Jackevicius, Cynthia A. [1 ,3 ,4 ,6 ]
机构：
[1] Western Univ Hlth Sci, Coll Pharm, Pomona, CA 91766 USA
[2] Univ Calif Irvine, Sch Pharm & Pharmaceut Sci, Irvine, CA USA
[3] ICES, Toronto, ON, Canada
[4] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Toronto, ON, Canada
[6] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2024年 / 226卷
基金：
加拿大健康研究院;
关键词：
clopidogrel; ticagrelor; adherence; persistence; acute coronary syndromes; P2Y12; inhibitors;
D O I：
10.1016/j.amjcard.2024.04.047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：134 / 136
页数：3
相关论文
共 50 条
  • [11] Choice of P2Y12 Inhibitors After Acute Coronary Syndrome
    Ando, Giuseppe
    Gragnano, Felice
    Pelliccia, Francesco
    Calabro, Paolo
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 211 : 377 - 377
  • [12] P2Y12 Inhibitor Adherence Patterns in Patients with Acute Coronary Syndrome
    Ozaki, Aya
    Ko, Dennis T.
    Chong, Alice
    Fang, Jiming
    Austin, Peter
    Sud, Maneesh
    Jackevicius, Cynthia A.
    CIRCULATION, 2021, 144
  • [13] P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa
    Alexopoulos, Dimitrios
    CARDIOLOGY, 2014, 127 (04) : 211 - 219
  • [14] Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations
    Jukema, J. Wouter
    Lettino, Maddalena
    Widimsky, Petr
    Danchin, Nicolas
    Bardaji, Alfredo
    Barrabes, Jose A.
    Cequier, Angel
    Claeys, Marc J.
    De Luca, Leonardo
    Doerler, Jakob
    Erlinge, David
    Erne, Paul
    Goldstein, Patrick
    Koul, Sasha M.
    Lemesle, Gilles
    Luescher, Thomas F.
    Matter, Christian M.
    Montalescot, Gilles
    Radovanovic, Dragana
    Lopez-Sendon, Jose
    Tousek, Petr
    Weidinger, Franz
    Weston, Clive F. M.
    Zaman, Azfar
    Zeymer, Uwe
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2015, 1 (04) : 232 - 244
  • [15] Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI
    Capodanno, Davide
    Angiolillo, Dominick J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (01) : 1 - 18
  • [16] Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis, Georgios
    Baber, Usman
    Mehran, Roxana
    CURRENT OPINION IN CARDIOLOGY, 2014, 29 (04) : 301 - 306
  • [17] Adherence to P2Y12 inhibitors in acute coronary syndrome after a percutaneous coronary intervention: what can we improve?
    Han, Yaling
    Li, Yang
    EUROPEAN HEART JOURNAL, 2022, 43 (24) : 2314 - 2316
  • [18] Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes
    Joshi, Rajiv R.
    Hossain, Rashed
    Morton, Allison C.
    Ecob, Rosemary
    Judge, Heather M.
    Wales, Clare
    Walker, Jemma V.
    Karunakaran, Arun
    Storey, Robert F.
    PLATELETS, 2014, 25 (06) : 416 - 422
  • [19] Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes
    Serebruany, V. L.
    EUROPEAN HEART JOURNAL, 2013, 34 : 470 - 471
  • [20] P2Y12 inhibitors in acute coronary syndromes: How do we choose the best drug for our patients?
    Kristensen, Steen D.
    Grove, Erik L.
    Hvas, Anne-Mette
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) : 203 - 205
12345